ALS Canada expands national genetics strategy with TD support to improve care and counselling.

ALS Canada, with renewed funding from TD Bank, is advancing its national strategy for ALS genetics to enhance access to genetic information, counselling, and care for Canadians affected by or at risk of ALS. This builds on the 2024 pilot of the first ALS National Genetic Counsellor role, which supports people with ALS and their families through education and testing. The initiative aims to develop Canadian-specific genetics guidelines and new care models, reflecting advances in ALS research and treatment, including therapies that slow disease progression. The effort seeks to provide comprehensive support and improve outcomes for nearly 4,000 Canadians living with ALS and those genetically at risk.

TD Bank shares are trading at USD 124.50 as of Nov 12, 2026 21:11 WIB on Pluang, close to their 52-week high of USD 128.20 and well above the 52-week low of USD 81.32. The stock's modest 1-day gain of 0.18% contrasts with its strong dividend yield of 2.58%, highlighting steady income potential alongside price stability. This stable performance provides a backdrop to TD's ongoing support for ALS Canada’s national genetics strategy.